Replies to post #398013 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Reverse splits can be investor friendly, if not too Draconian, and timed after very very good news.

Let’s just pretend my wildest dream for trial results occur.

All endpoints pass, which would mean certain approval of the primary as confirmed by the secondary OS treatment versus placebo, AND

rGBM endpoint tentatively confirmed by combo trial early data.

Boom, new cancer platform, price spikes well into double digits, reverse split announced 6 to 1 so price more attractive to more people. Thus no severe dilution and your stock portfolio keeps increasing. No more outstanding share issues.

Speculative investors eager to see surrogate rapid trials in all operable cancer indications. Yadayadayada.